FDA approves First RSV vaccine for adults under 60

US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.
FDA approves 1st RSV vaccine for adults under 60
The expansion builds on the previous indication for adults 60 years and older. The vaccine is also approved for pregnant individuals to protect infants from birth up to six months. With the decision,
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
A new COVID-19 vaccine has been approved for Australians. Here's what to know
The Therapeutic Goods Administration has given Pfizer's new COVID-19 jab the green light. But what about vaccines from ...
As new COVID-19 strains emerge, how do vaccine manufacturers keep up with mutations of the virus?
New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...
Pharmaceutical Technology on MSN1d
A slow start for self-amplifying mRNA vaccines
A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.
Australian Associated Press2d
No, Japan has not declared a state of emergency after ‘nanobot discovery’ in COVID vaccines
Social media users are spreading new levels of misinformation based on discredited claims that nanobots are lurking in ...
The Washington Post10d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.
Does the updated Pfizer COVID-19 vaccine protect against the XEC variant?
Bogoch says the latest vaccine was designed for a sublineage of Omicron called KP.2, which began circulating several months ...
Pfizer faces showdown with $1.5 billion activist investor after post-Covid share plunge
Pfizer is facing a messy showdown this week after an outside bid to revive the company’s post-Covid share plunge took an ...
He Made Pfizer a Household Name. Wall Street Wants More.
With Pfizer’s stock down sharply, an activist investor is pushing for CEO Albert Bourla to improve performance.
Reuters29d
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to ...